Literature DB >> 15928361

Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study.

Dominic H Lam1, Paul McCrone, Kim Wright, Natalie Kerr.   

Abstract

BACKGROUND: We have reported the advantageous clinical outcome of adding cognitive therapy to medication in the prevention of relapse of bipolar disorder. AIMS: This 30-month study compares the cost-effectiveness of cognitive therapy with standard care.
METHOD: We randomly allocated 103 individuals with bipolar 1 disorder to standard treatment and cognitive therapy plus standard treatment. Service use and costs were measured at 3-month intervals and cost-effectiveness was assessed using the net-benefit approach.
RESULTS: The group receiving cognitive therapy had significantly better clinical outcomes. The extra costs were offset by reduced service use elsewhere. The probability of cognitive therapy being cost-effective was high and robust to different therapy prices.
CONCLUSIONS: Combination of cognitive therapy and mood stabilizers was superior to mood stabilizers alone in terms of clinical outcome and cost-effectiveness for those with frequent relapses of bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928361     DOI: 10.1192/bjp.186.6.500

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

1.  More than medication-achieving psychotherapy goals in patients with bipolar disorder in challenging settings.

Authors:  Brenda J B Roman; Paulette Marie Gillig
Journal:  Psychiatry (Edgmont)       Date:  2006-03

2.  Psychotherapy for Bipolar Disorder in Adults: A Review of the Evidence.

Authors:  Holly A Swartz; Joshua Swanson
Journal:  Focus (Am Psychiatr Publ)       Date:  2014

3.  Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.

Authors:  Krista A Payne; Gail Myhr
Journal:  Healthc Policy       Date:  2010-02

4.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

Review 5.  Pharmacotherapy of bipolar disorder in children and adolescents: recent progress.

Authors:  Jonathan C Pfeifer; Robert A Kowatch; Melissa P DelBello
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 6.  Bipolar disorder: what can psychotherapists learn from the cognitive research?

Authors:  Sheri Johnson; Tanya Tran
Journal:  J Clin Psychol       Date:  2007-05

7.  Cost-Effectiveness Evaluations of Psychological Therapies for Schizophrenia and Bipolar Disorder: A Systematic Review.

Authors:  Gemma Elizabeth Shields; Deborah Buck; Jamie Elvidge; Karen Petra Hayhurst; Linda Mary Davies
Journal:  Int J Technol Assess Health Care       Date:  2019-07-22       Impact factor: 2.188

8.  Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.

Authors:  Jeffrey S Hoch; Marie Antoinette Rockx; Andrew D Krahn
Journal:  BMC Health Serv Res       Date:  2006-06-06       Impact factor: 2.655

9.  Psychosocial treatment and interventions for bipolar disorder: a systematic review.

Authors:  Stella Miziou; Eirini Tsitsipa; Stefania Moysidou; Vangelis Karavelas; Dimos Dimelis; Vagia Polyzoidou; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2015-07-07       Impact factor: 3.455

10.  Maladaptive personality traits and the course of suicidal ideation in young adults with bipolar disorder: Cross-sectional and prospective approaches.

Authors:  Anastacia Y Kudinova; Heather A MacPherson; Katharine Musella; Elana Schettini; Anna C Gilbert; Gracie A Jenkins; Lee Anna Clark; Daniel P Dickstein
Journal:  Suicide Life Threat Behav       Date:  2020-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.